Idioma:

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Louapre, Céline ; Collongues, Nicolas ; Stankoff, Bruno ; Giannesini, Claire ; Papeix, Caroline ; Bensa, Caroline ; Deschamps, Romain ; Créange, Alain ; Wahab, Abir ; Pelletier, Jean ; Heinzlef, Olivier ; Labauge, Pierre ; Guilloton, Laurent ; Ahle, Guido ; Goudot, Mathilde ; Bigaut, Kevin ; Laplaud, David-Axel ; Vukusic, Sandra ; Lubetzki, Catherine ; De Sèze, Jérôme

Archives of neurology (Chicago), 2020-09, Vol.77 (9), p.1079-1088 [Periódico revisado por pares]

United States: American Medical Association

Texto completo disponível

Citações Citado por

Enviar para

Título:
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
Autor: Louapre, Céline ; Collongues, Nicolas ; Stankoff, Bruno ; Giannesini, Claire ; Papeix, Caroline ; Bensa, Caroline ; Deschamps, Romain ; Créange, Alain ; Wahab, Abir ; Pelletier, Jean ; Heinzlef, Olivier ; Labauge, Pierre ; Guilloton, Laurent ; Ahle, Guido ; Goudot, Mathilde ; Bigaut, Kevin ; Laplaud, David-Axel ; Vukusic, Sandra ; Lubetzki, Catherine ; De Sèze, Jérôme
Assuntos: Adult ; Age ; Betacoronavirus ; Chronology ; Cohort Studies ; Comments ; Computed tomography ; Coronavirus Infections - epidemiology ; Coronavirus Infections - therapy ; Coronaviruses ; COVID-19 ; Demographics ; Demography ; Emerging diseases ; Exposure ; Female ; France - epidemiology ; Health risks ; Human health and pathology ; Humans ; Infectious diseases ; Life Sciences ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - therapy ; Multivariate analysis ; Neurons and Cognition ; Obesity ; Online First ; Original Investigation ; Pandemics ; Patients ; Plaques ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - therapy ; Polymerase chain reaction ; Registries ; Regression analysis ; Regression models ; Retrospective Studies ; Risk analysis ; Risk factors ; SARS-CoV-2 ; Signs and symptoms ; Thorax ; Treatment Outcome ; Viral diseases
É parte de: Archives of neurology (Chicago), 2020-09, Vol.77 (9), p.1079-1088
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMCID: PMC7320356
Descrição: IMPORTANCE: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. OBJECTIVE: To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity. DESIGN, SETTING, AND PARTICIPANTS: The Covisep registry is a multicenter, retrospective, observational cohort study conducted in MS expert centers and general hospitals and with neurologists collaborating with MS expert centers and members of the Société Francophone de la Sclérose en Plaques. The study included patients with MS presenting with a confirmed or highly suspected diagnosis of COVID-19 between March 1, 2020, and May 21, 2020. EXPOSURES: COVID-19 diagnosed with a polymerase chain reaction test on a nasopharyngeal swab, thoracic computed tomography, or typical symptoms. MAIN OUTCOMES AND MEASURES: The main outcome was COVID-19 severity assessed on a 7-point ordinal scale (ranging from 1 [not hospitalized with no limitations on activities] to 7 [death]) with a cutoff at 3 (hospitalized and not requiring supplemental oxygen). We collected demographics, neurological history, Expanded Disability Severity Scale score (EDSS; ranging from 0 to 10, with cutoffs at 3 and 6), comorbidities, COVID-19 characteristics, and outcomes. Univariate and multivariate logistic regression models were used to estimate the association of collected variables with COVID-19 outcomes. RESULTS: A total of 347 patients (mean [SD] age, 44.6 [12.8] years, 249 women; mean [SD] disease duration, 13.5 [10.0] years) were analyzed. Seventy-three patients (21.0%) had a COVID-19 severity score of 3 or more, and 12 patients (3.5%) died of COVID-19. The median EDSS was 2.0 (range, 0-9.5), and 284 patients (81.8%) were receiving DMT. There was a higher proportion of patients with a COVID-19 severity score of 3 or more among patients with no DMT relative to patients receiving DMTs (46.0% vs 15.5%; P < .001). Multivariate logistic regression models determined that age (odds ratio per 10 years: 1.9 [95% CI, 1.4-2.5]), EDSS (OR for EDSS ≥6, 6.3 [95% CI. 2.8-14.4]), and obesity (OR, 3.0 [95% CI, 1.0-8.7]) were independent risk factors for a COVID-19 severity score of 3 or more (indicating hospitalization or higher severity). The EDSS was associated with the highest variability of COVID-19 severe outcome (R2, 0.2), followed by age (R2, 0.06) and obesity (R2, 0.01). CONCLUSIONS AND RELEVANCE: In this registry-based cohort study of patients with MS, age, EDSS, and obesity were independent risk factors for severe COVID-19; there was no association found between DMTs exposure and COVID-19 severity. The identification of these risk factors should provide the rationale for an individual strategy regarding clinical management of patients with MS during the COVID-19 pandemic.
Editor: United States: American Medical Association
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 9 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

United States: American Medical Association

Buscando em bases de dados remotas. Favor aguardar.